In confirmed hypertrophic cardiomyopathy (HCM) without JAK2-V617F mutation, upregulated expression of JAK2 in the global left ventricle (LV) and cardiomyocyte nuclei was observed, along with activation of its downstream target STAT3 (50). This evidence concerns the gene STAT3 and hypertrophic cardiomyopathy.